References
- FDA announces safety labeling changes and postmarket study requirements for extended-release and long-acting opioid analgesics. Silver Spring (MD): US Food and Drug Administration; 2013 [cited 2016 Oct 28]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnoucements/ucm367726.htm
- Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. MMWR Recomm Rep. 2016;65(No. RR–1):1–49.
- FDA announces enhanced warnings for immediate-release opioids pain medications related to risks of misuse, abuse, addiction, overdose, and death. Silver Spring (MD: US Food and Drug Administration; 2016 [cited 2016 Oct 28]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnoucements/ucm491739.htm
- Tallarida RJ, Cowan A, Raffa RB. On deriving the dose-effect relation of an unknown second component: an example using buprenorphine preclinical data. Drug Alcohol Depend. 2010;109:126–129.
- Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend. 2014;144:1–11.
- Suboxone, [package insert]. Richmond (VA): Reckitt Benckiser Pharmaceuticals; 2016.
- Subutex, [package insert]. Richmond (VA): Reckitt Benckiser Pharmaceuticals; 2016.
- Butrans [package insert]. Stamford (CT): Purdue Pharma L.P.; 2014.